State-of-the-art Imaging Biomarkers
for Parkinson's Disease
QMENTA has amassed the most advanced and widely used imaging biomarkers on its platform to enable experts to measure the efficacy of treatments under trial or research in a single environment.
Identification of atrophy at specific parts of the brain gives valuable insight for the diagnosis of Parkinson's and the differentiation of its variants.Back to biomarkers
Gray Matter Volume and Thickness Quantification
Particular brain structure atrophy patterns appear in longitudinal MRI specific to Parkinsonian variants such as progressive supranuclear palsy (PSP) and multiple system atrophy (MSA), thus identifying cortical atrophy measurements from T1 weighted MRI is as a promising potential biomarker for Parkinson’ disease (PD)(9,10). The QMENTA platform’s gray matter volumetry tools allow for quantification of region-specific gray matter volume for each patient timepoint using processing tools such as FreeSurfer, ANTs and SIENAX. The platform’s data management allows longitudinal assessment of gray matter atrophy.
Hippocampal and Basal Ganglia Volumetry
Hippocampal and striatal volumetric reductions have been observed in PD patients.(8) The QMENTA platform offers tools for volumetric quantification of basal ganglia structures and hippocampal subfields, including hi-resolution hippocampal image quantification.
8. Saeed, Usman, et al. "Imaging biomarkers in Parkinson’s disease and Parkinsonian syndromes: current and emerging concepts." Translational neurodegeneration 6.1 (2017): 8.
9. Claassen, Daniel O., et al. "Cortical asymmetry in Parkinson's disease: early susceptibility of the left hemisphere." Brain and behavior 6.12 (2016): e00573.
10. Hwang, Kristy S., et al. "Mapping cortical atrophy in Parkinson's disease patients with dementia." Journal of Parkinson's disease 3.1 (2013): 69-76.